Structure-antitumor activity relationships among quinone derivatives.
D000818:Animals; D000880:Anthraquinones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D003630:Daunorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use; D009285:Naphthoquinones / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011809:Quinones / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000188:drug therapy; D013308:Streptonigrin / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000880:Anthraquinones; D000970:Antineoplastic Agents; D001389:Azirines; D001952:Bridged-Ring Compounds; D006571:Heterocyclic Compounds; D008937:Mitomycins; D009285:Naphthoquinones; D011809:Quinones; D013308:Streptonigrin; D007770:L-Lactate Dehydrogenase; D003630:Daunorubicin